Clinical Trials Browser

Phase 2 × Carcinoma, Transitional Cell × anlotinib × Clear all

NCT05030077 2021-09-01

Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma

Phase 2 Unknown

Carcinoma, Transitional Cell, Urogenital Neoplasms